✦ LIBER ✦

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Scribed by Vaddi, Kris; Sarlis, Nicholas J; Gupta, Vikas

Book ID: 120185982
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 545 KB
Volume: 13
Category: Article
ISSN: 1465-6566
DOI: 10.1517/14656566.2012.732998

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Allogeneic hematopoietic cell transplant

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

✍ Jaekel, N; Behre, G; Behning, A; Wickenhauser, C; Lange, T; Niederwieser, D; Al- 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Myelofibrosis, JAK2 inhibitors and eryth

Myelofibrosis, JAK2 inhibitors and erythropoiesis

✍ Vainchenker, W; Favale, F 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 339 KB

Ruxolitinib: a new JAK1/2 inhibitor that

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis

✍ Ostojic, Alen; Vrhovac, Radovan; Verstovsek, Srdan 📂 Article 📅 2011 🏛 Future Medicine 🌐 English ⚖ 451 KB

Therapy with JAK 1/2 inhibitors for myel

Therapy with JAK 1/2 inhibitors for myelofibrosis

✍ Franz Romeder MD, Richard Greil… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 277 KB

Safety and Efficacy of INCB018424, a JAK

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

✍ Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cor 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 542 KB

Safety and efficacy of CYT387, a JAK1 an

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Pardanani, A; Laborde, R R; Lasho, T L; Finke, C; Begna, K; Al-Kali, A; Hogan, W 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 510 KB